---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-057481"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:50:01.248093+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude prioritizes SMARCA2 and CDK9, partners with AbCellera on ADCs, reports Q3 net loss $30.6M

## Summary
- Q3 net loss $30.6M ($0.45/share); cash at $230.5M; cash runway into 2026.
- Prioritizing PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) for continued development.
- Discontinuation of MCL-1 (PRT1419) and CDK4/6 (PRT3645) programs; seeking partners for PRT3645.
- Entered partnership with AbCellera to develop precision ADCs using SMARCA payloads.
- Expects initial Phase 1 data for SMARCA2 and CDK9 in mid-2024.

## SEC filing metadata
- accession: 0000950170-23-057481
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017023057481/0000950170-23-057481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017023057481/prld-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-057481
- JSON: https://secwatch.observer/filing/0000950170-23-057481.json
- Plain text: https://secwatch.observer/filing/0000950170-23-057481.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for the three months ended September 30, 2023.
  - Period: the three months ended September 30, 2023
  - Result: reported results
  source text: On November 1, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017023057481/0000950170-23-057481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.